Thomas G. Frinzi

President, CEO, and Chair of the Board at STAAR Surgical Co

Board

Since January 1, 2023

Age

68 years

Education

Earned a Bachelor of Arts (B.A.) from the University of Tampa.

Tenure

Joined STAA as a Board member in June 2020 , was appointed Chair of the Board in June 2022 , and assumed the role of President and CEO on January 1, 2023.

Also at STAAR Surgical Co

KHP

Keith Holliday, Ph.D.

Chief Technology Officer (CTO)

NBSE

Nathaniel B. Sisitsky, Esq.

General Counsel and Corporate Secretary

PFW

Patrick F. Williams

Chief Financial Officer (CFO)

About

Thomas G. Frinzi is 68 years old and has built a robust foundation in the ophthalmic and medical device sectors, where his leadership and innovative strategies have played a significant role in transforming the industry.

With extensive experience spanning multiple leadership roles at large corporations and start-ups alike, his career reflects a commitment to excellence in international sales, marketing, and executive management. His roles at companies such as Bausch & Lomb Surgical, WaveTec Vision, Abbott Medical Optics, and Johnson & Johnson Vision have equipped him with a deep operational and strategic insight into the challenges and opportunities of the ophthalmic field.

At STAA, his journey began when he joined as a Board member in June 2020, later progressing to Chair of the Board in June 2022, and culminating in his appointment as President and CEO on January 1, 2023. His tenure at the company is marked by a blend of visionary leadership and practical experience, driving growth and operational excellence in a competitive market.

$STAA Performance Under Thomas G. Frinzi

Past Roles

Organization	Role	Date Range	Details
STAAR Surgical Company (STAA)	Chair of the Board	June 2022 - December 2022	Appointed as Chair prior to becoming President & CEO
STAAR Surgical Company (STAA)	Board Member	June 2020 - June 2022	Served as a Board member before subsequent appointments
CorneaGen	Executive Chair of the Board of Directors	Joined August 2020	Oversaw development of therapeutics for corneal disease
Johnson & Johnson Vision	Worldwide President, Surgical	February 2017 - December 2019	Managed a broad ophthalmology portfolio
Abbott Medical Optics (AMO)	Senior Vice President of Abbott Laboratories and President of AMO	January 2016 - February 2017	AMO was acquired by Johnson & Johnson
Alcon	Head of WaveTec Vision	September 2014 - July 2015	Led continued leadership after acquisition of WaveTec Vision
WaveTec Vision	President and CEO	September 2010 - September 2014	Led development of surgical systems; later acquired by Alcon
Bausch & Lomb Surgical, Refractec, Chiron Vision, and Johnson & Johnson	Senior Positions in Commercial Operations, Business Development, and Sales & Marketing	N/A	Held various senior roles

Fixed Compensation

Data from FY 2023

Component Name	Amount	Payment Schedule	Additional Details
Base Salary	$820,000	Annual	Fixed base salary for 2023.
Severance Payment	$1,230,000	18 monthly installments	18 months of base salary if terminated without cause or if resigns for good reason.
COBRA Premiums	$0	N/A	Declined health care benefits in 2023.

Performance Compensation

Data from FY 2023

Annual Cash Bonus

Metric	Target / Value	Additional Details
Revenue Target	$355 million	Revenue performance metric as set in the 2023 Bonus Plan.
Adjusted EBITDA per Share Target	$1.30	EBITDA per Share performance target defined in the 2023 Bonus Plan.
Funding Level	50%	Due to actual results of $322.4M revenue and $1.15 EBITDA per share, the bonus pool was funded at 50%.
Base Salary	$820,000	Base used for bonus calculation.
Target Bonus Percentage	105%	Bonus percentage based on base salary.
Target Bonus Amount	$861,000	Calculated as 105% of the base salary.
Earned Bonus Payment	$430,500	50% of the target bonus amount due to performance shortfall.

Note: The Annual Cash Bonus is part of STAAR's 2023 Bonus Plan, a non-equity incentive plan award without any related grant date, vesting schedule, or equity component.